Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(H Share Stock Code: 0874)

FURTHER ANNOUNCEMENT IN RELATION TO THE MAJOR ASSETS REORGANIZATION AND RESUMPTION OF TRADING

References are made to the announcements of Guangzhou Pharmaceutical Company Limited (the "Company") dated 27 March 2012, 18 June 2012, 24 August 2012, 17 September 2012, 19 September 2012, 16 October 2012 and 23 November 2012 respectively and the circular of the Company dated 4 September 2012 (the "Circular") in relation to the Major Assets Reorganization. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

On 30 November 2012, the Company was notified by CSRC that the Major Assets Reorganization was approved unconditionally by the Merger and Reorganization Audit Committee of Listed Companies of CSRC at its thirty-third meeting in 2012.

At the request of the Company, trading of the H Shares on the Hong Kong Stock Exchange has been suspended with effect from 9:00 a.m. on 23 November 2012, pending the release of this announcement. The Company has made an application to the Hong Kong Stock Exchange for the resumption of trading of H Shares on the Hong Kong Stock Exchange with effect from 9:00 a.m. on 3 December 2012. The Company will make a further announcement after receiving the formal approval documents from the CSRC.

Trading in the A Shares of the Company on The Shanghai Stock Exchange will also resume on the same day (i.e. 3 December 2012).

The Board of **Guangzhou Pharmaceutical Company Limited**

Guangzhou, the PRC, 30 November 2012

As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan, Ms. Cheng Ning and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.